420 with CNW – Study Finds Cannabis Flower Tops Other Cannabis Products in Providing Pain Relief

August 22, 2019 15:20:05

A study whose findings were published towards the end of July has found that dried marijuana flower provides the highest level of pain relief when compared to other marijuana products. This conclusion was made after analyzing the data collected by an app which allows medical marijuana users to track the effects of the different medical marijuana products and dosage for different health conditions.

The New Mexico University researchers wrote that higher THC concentrations in marijuana flower and other cannabis products were associated with better pain relief outcomes among the patients who used the Releaf App to track their medical cannabis usage.

In contrast, CBD showed pain relief effects only up to a certain level, while the additional concentration was associated with no additional benefit yet gastrointestinal complaints increased among the patients who used products with higher concentrations of CBD. This is in line with research that shows the benefits of CBD start leveling off when patients consume higher doses of the compound.

Overall, the study looked at 20,513 sessions of marijuana use logged in the app by 2,987 patients for more than two years (June 6, 2016 to October 24, 2018). 95 percent of all the patients reported marked relief from pain and the average reduction was 3.1 points on a self-reported pain scale ranging from 0-10. The starting level of pain was an average of 5.87 and this average dropped to 2.77 after the patients had used marijuana for their pain.

Another highlight of this study was that cannabis concentrates were linked to more side effects than dried cannabis flower. The researchers suspect that those negative side effects could have been caused by the residues of the solvents used to extract the concentrates, or because other cannabis compounds, such as terpenes and flavonoids, are lost during the extraction process.

The research also revealed that marijuana products which were hybrids of sativa and indica marijuana strains exhibited better pain management when compared to those that were either purely indica or purely sativa in nature.

It was also noted that the patients who said that they had pain in the stomach or gastrointestinal system benefited most from products with lower concentrations of THC than from products high in THC.

Interestingly, the patients who used marijuana tinctures, pills and edibles reported less relief from pain when compared to those who used cannabis concentrates, dried flower and topical products.

This research done on a large population of medical marijuana users provides some of the best proof so far available regarding the role of THC in pain management. Industry watchers are eager to see how different entities like Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) and TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) will make use of these research findings in their products.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

Denver, Colorado
303.498.7722 Office